| Characteristics . | Summary statistics (n = 52), n (%) . |
|---|---|
| Female sex | 52 (100) |
| Median age (range), years | 55 (33–79) |
| White race | 42 (81) |
| ECOG performance status | |
| 0 | 37 (71) |
| 1 | 15 (29) |
| Estrogena/progesterone receptors | |
| ER+/PgR+ | 40 (77) |
| ER+/PgR− | 12 (23) |
| Sites of disease | |
| Bone only | 18 (35) |
| Bone + others | 34 (65) |
| Liver | 5 (10) |
| Lung/pleura | 7 (13) |
| Brain | 0 |
| One other site | 8 (15) |
| ≥2 other sites | 14 (27) |
| Prior lines of endocrine therapy for metastatic disease | |
| 0 | 7 (13) |
| 1 | 17 (33) |
| 2–4 | 28 (54) |
| Prior lines of chemotherapy for metastatic disease | |
| 0 | 15 (29) |
| 1 | 15 (29) |
| 2–9 | 22 (42) |
| Prior therapy of bone modifying agents | 35 (67) |
| Bisphosphonates | 34 (65) |
| Denosumab | 5 (10) |
| Characteristics . | Summary statistics (n = 52), n (%) . |
|---|---|
| Female sex | 52 (100) |
| Median age (range), years | 55 (33–79) |
| White race | 42 (81) |
| ECOG performance status | |
| 0 | 37 (71) |
| 1 | 15 (29) |
| Estrogena/progesterone receptors | |
| ER+/PgR+ | 40 (77) |
| ER+/PgR− | 12 (23) |
| Sites of disease | |
| Bone only | 18 (35) |
| Bone + others | 34 (65) |
| Liver | 5 (10) |
| Lung/pleura | 7 (13) |
| Brain | 0 |
| One other site | 8 (15) |
| ≥2 other sites | 14 (27) |
| Prior lines of endocrine therapy for metastatic disease | |
| 0 | 7 (13) |
| 1 | 17 (33) |
| 2–4 | 28 (54) |
| Prior lines of chemotherapy for metastatic disease | |
| 0 | 15 (29) |
| 1 | 15 (29) |
| 2–9 | 22 (42) |
| Prior therapy of bone modifying agents | 35 (67) |
| Bisphosphonates | 34 (65) |
| Denosumab | 5 (10) |
aER+ in either metastatic lesions (45 patients) or primary tissues (7 patients).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER+, estrogen receptor positive; PgR, progesterone receptor.
| Characteristics . | Summary statistics (n = 52), n (%) . |
|---|---|
| Female sex | 52 (100) |
| Median age (range), years | 55 (33–79) |
| White race | 42 (81) |
| ECOG performance status | |
| 0 | 37 (71) |
| 1 | 15 (29) |
| Estrogena/progesterone receptors | |
| ER+/PgR+ | 40 (77) |
| ER+/PgR− | 12 (23) |
| Sites of disease | |
| Bone only | 18 (35) |
| Bone + others | 34 (65) |
| Liver | 5 (10) |
| Lung/pleura | 7 (13) |
| Brain | 0 |
| One other site | 8 (15) |
| ≥2 other sites | 14 (27) |
| Prior lines of endocrine therapy for metastatic disease | |
| 0 | 7 (13) |
| 1 | 17 (33) |
| 2–4 | 28 (54) |
| Prior lines of chemotherapy for metastatic disease | |
| 0 | 15 (29) |
| 1 | 15 (29) |
| 2–9 | 22 (42) |
| Prior therapy of bone modifying agents | 35 (67) |
| Bisphosphonates | 34 (65) |
| Denosumab | 5 (10) |
| Characteristics . | Summary statistics (n = 52), n (%) . |
|---|---|
| Female sex | 52 (100) |
| Median age (range), years | 55 (33–79) |
| White race | 42 (81) |
| ECOG performance status | |
| 0 | 37 (71) |
| 1 | 15 (29) |
| Estrogena/progesterone receptors | |
| ER+/PgR+ | 40 (77) |
| ER+/PgR− | 12 (23) |
| Sites of disease | |
| Bone only | 18 (35) |
| Bone + others | 34 (65) |
| Liver | 5 (10) |
| Lung/pleura | 7 (13) |
| Brain | 0 |
| One other site | 8 (15) |
| ≥2 other sites | 14 (27) |
| Prior lines of endocrine therapy for metastatic disease | |
| 0 | 7 (13) |
| 1 | 17 (33) |
| 2–4 | 28 (54) |
| Prior lines of chemotherapy for metastatic disease | |
| 0 | 15 (29) |
| 1 | 15 (29) |
| 2–9 | 22 (42) |
| Prior therapy of bone modifying agents | 35 (67) |
| Bisphosphonates | 34 (65) |
| Denosumab | 5 (10) |
aER+ in either metastatic lesions (45 patients) or primary tissues (7 patients).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER+, estrogen receptor positive; PgR, progesterone receptor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
